Orexin B is a research-only peptide with no approved human dose. There is no medically established schedule; any amounts seen online are anecdotal and not standardized. This is education, not a personal protocol.
Overview
Orexin B (hypocretin-2) is a signaling peptide involved in wakefulness and arousal. Compared with orexin A, it preferentially acts on the OX2 receptor and is described as shorter-lived and less chemically stable. It is a research compound, not an approved medicine, and it has not gone through dose-finding clinical trials — so there is no established dose.
Is there a common dose?
Honestly, no standardized common dose exists:
- No established dose — orexin B has no approved or clinically validated amount, and figures shared online vary widely and are not standardized.
- Lower stability — because it is described as less chemically stable than orexin A, how much intact peptide is present is a particular unknown.
- Start low, with supervision — if handled at all, it belongs in controlled research under expert oversight, not self-experimentation.
We deliberately do not cite a number here, because a specific figure would imply a standard that does not exist.
How it is discussed
Discussion of orexin B centers on its receptor selectivity (OX2R) and its limited stability. Both are open research themes rather than settled administration instructions, and its rapid breakdown means exposure is hard to predict from any stated amount.
Why supervision matters
Orexin B acts on arousal circuitry, and its safety profile, interactions, and appropriate candidates are not characterized in humans. There is no approved indication or monitoring standard. Any real-world handling belongs within controlled research under expert supervision — not a self-directed protocol.